Del-desiran (AOC 1001)
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myotonic Dystrophy Type 1
Conditions
Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia, Myotonic Dystrophy 1, Myotonic Disorders, Steinert Myotonic Dystrophy, Steinert Disease
Trial Timeline
Jul 25, 2025 → Oct 1, 2030
NCT ID
NCT07008469About Del-desiran (AOC 1001)
Del-desiran (AOC 1001) is a phase 3 stage product being developed by Avidity Biosciences for Myotonic Dystrophy Type 1. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07008469. Target conditions include Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07008469 | Phase 3 | Recruiting |
Competing Products
16 competing products in Myotonic Dystrophy Type 1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib | AMO Pharma | Phase 2 | 44 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| VX-670 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-670 + Placebo | Vertex Pharmaceuticals | Phase 1/2 | 40 |
| SAR446268 | Sanofi | Phase 1/2 | 40 |
| rhIGF-I/rhIGFBP-3 + placebo | Insmed | Phase 2 | 49 |
| IONIS-DMPKRx + Placebo | Ionis Pharmaceuticals | Phase 1/2 | 38 |
| ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) Injection | Arrowhead Pharmaceuticals | Phase 1/2 | 38 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 3 | 72 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 1/2 | 36 |
| Pitolisant Oral Tablet + Placebo oral tablet | Harmony Biosciences | Phase 2 | 47 |
| PGN-EDODM1 | PepGen | Phase 2 | 44 |
| PGN-EDODM1 | PepGen | Phase 2 | 44 |
| PGN-EDODM1 for infusion | PepGen | Phase 1 | 25 |